These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 9644978)

  • 1. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
    Lopatkin NA; Loran OB; Pushkar' DIu; Perepanova TS; Tevlin KP
    Urol Nefrol (Mosk); 1998; (3):3-5. PubMed ID: 9644978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Doksazozin "Cardura" in acute urinary retention caused by benign prostatic hyperplasia].
    Perepanova TS; Kamalov AA; Siniukhin VN; Gorokhnov AV; Khazan PL; Orlova EV
    Urologiia; 2001; (3):18-20. PubMed ID: 11505534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
    Chung BH; Hong SJ; Lee MS
    Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ambulatory urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
    Gerber GS; Contreras BA; Rukstalis DB
    Tech Urol; 1997; 3(3):164-7. PubMed ID: 9422449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
    Dutkiewicz S
    Mater Med Pol; 1995; 27(4):151-2. PubMed ID: 9000839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effectiveness and safety of combined therapy with an alpha-blocker and an anticholinergic drug for patients with benign prostatic hyperplasia].
    Xiao H; Li HZ; Huang ZM; Li YQ
    Zhonghua Wai Ke Za Zhi; 2010 Dec; 48(23):1771-3. PubMed ID: 21211380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxazosin-alpha-1-adrenergic antagonists drug in the long-term (3 years). Management of benign prostatic hyperplasia.
    Dutkiewicz S
    Mater Med Pol; 1996; 28(3):93-102. PubMed ID: 9167419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
    Xue Z; Zhang Y; Ding Q; He Z; Wang J; Xu K
    Int J Urol; 2007 Feb; 14(2):118-22. PubMed ID: 17302567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies.
    Mobley DF; Kaplan S; Ice K; Gaffney M; Dias N
    Int J Clin Pract; 1997; 51(5):282-8. PubMed ID: 9489085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.
    Gillenwater JY; Conn RL; Chrysant SG; Roy J; Gaffney M; Ice K; Dias N
    J Urol; 1995 Jul; 154(1):110-15. PubMed ID: 7539854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
    Esteban Fuertes M; Salinas Casado J; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
    Arch Esp Urol; 1997 Dec; 50(10):1057-66. PubMed ID: 9494194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of doxazosin in patients with benign prostatic hyperplasia.
    Janknegt RA
    Scand J Urol Nephrol Suppl; 1995; 168():21-7. PubMed ID: 7541548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
    Mazo EB; Matushevskiĭ IA; Nikitin IuIu
    Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The doxazosin treatment of the changes in the bladder filling phase in benign prostatic hyperplasia].
    Salinas Casado J; Esteban Fuertes M; Virseda Chamorro M; Ramírez Fernández JC; Salomón Moh'd S; Luengo Alpuente S; Resel Estévez L
    Arch Esp Urol; 1997 Oct; 50(8):840-5. PubMed ID: 9463281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release doxazosin for treatment of renal transplant recipients with benign prostatic hyperplasia.
    Zhang Y; Wang Y; Zhang P; Zhang XD; Yang Y
    Transplant Proc; 2009 Nov; 41(9):3747-51. PubMed ID: 19917379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
    Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
    Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of alpha1-adrenergic blockaders in treating voiding disorders after transurethral resection of the prostate].
    Martov AG; Gushchin BL; Oshchepkov VN; Ergakov DV
    Urologiia; 2002; (5 Suppl):23-37. PubMed ID: 12518670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.